Cargando…

Comparative Analysis of the Efficacy of Different Regimens of 12 Months Rifaximin-Alfa Therapy in Patients with Liver Cirrhosis and Minimal Hepatic Encephalopathy

It is a matter of current interest which rifaximin-α regimens in patients with liver cirrhosis and minimal hepatic encephalopathy are the most efficient. Study objective: to evaluate the effect of various rifaximin-α regimens for 12 months on clinical and laboratory parameters and quality of life in...

Descripción completa

Detalles Bibliográficos
Autores principales:	Bakulin, Igor G., Ivanova, Kristina N., Eremina, Elena Y., Marchenko, Natalya V.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2023
Materias:	Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10606376/ https://www.ncbi.nlm.nih.gov/pubmed/37892060 http://dx.doi.org/10.3390/diagnostics13203239

Ejemplares similares

Modulation of the Metabiome by Rifaximin in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Bajaj, Jasmohan S., et al.
Publicado: (2013)

RiMINI – the influence of rifaximin on minimal hepatic encephalopathy (MHE) and on the intestinal microbiome in patients with liver cirrhosis: study protocol for a randomized controlled trial
por: Schulz, Christian, et al.
Publicado: (2016)

Reversal of Low-Grade Cerebral Edema After Lactulose/Rifaximin Therapy in Patients with Cirrhosis and Minimal Hepatic Encephalopathy
por: Rai, Rahul, et al.
Publicado: (2015)

Rifaximin in the treatment of hepatic encephalopathy
por: Iadevaia, Maddalena Diana, et al.
Publicado: (2011)

Metabolic syndrome is associated with poor response to rifaximin in minimal hepatic encephalopathy
por: Ballester, María-Pilar, et al.
Publicado: (2022)

Rifaximin Alfa and Liver Diseases: More Than a Treatment for Encephalopathy, a Disease Modifier
por: Torre, Aldo, et al.
Publicado: (2023)

Rifaximin, Microbiota Biology, and Hepatic Encephalopathy
por: Peleman, Cedric, et al.
Publicado: (2016)

Primary prophylaxis of hepatic encephalopathy in decompensated cirrhosis: Low dose vs. full dose rifaximin
por: Sarwar, Shahid, et al.
Publicado: (2019)

Rifaximin Modulates the Gut Microbiota to Prevent Hepatic Encephalopathy in Liver Cirrhosis Without Impacting the Resistome
por: Yu, Xiao, et al.
Publicado: (2022)

Selective improvement by rifaximin of changes in the immunophenotype in patients who improve minimal hepatic encephalopathy
por: Mangas-Losada, Alba, et al.
Publicado: (2019)

Comparison of the effects of probiotics, rifaximin, and lactulose in the treatment of minimal hepatic encephalopathy and gut microbiota
por: Wang, Ming-Wei, et al.
Publicado: (2023)

Rifaximin as Treatment for Hepatic Encephalopathy: Some Considerations
por: Ridola, Lorenzo, et al.
Publicado: (2013)

The Use of Rifaximin in Patients With Cirrhosis
por: Caraceni, Paolo, et al.
Publicado: (2021)

Minimal Hepatic Encephalopathy in Indians: Psychometric Hepatic Encephalopathy Score and Inhibitory Control Test for Diagnosis and Rifaximin or Lactulose for Its Reversal
por: Pawar, Vinay B., et al.
Publicado: (2019)

Safety, efficacy, and patient acceptability of rifaximin for hepatic encephalopathy
por: Kimer, Nina, et al.
Publicado: (2014)

Cost-Effectiveness of Rifaximin Treatment in Patients with Hepatic Encephalopathy
por: Jesudian, Arun B., et al.
Publicado: (2020)

Predictors of Minimal Hepatic Encephalopathy in Patients with Cirrhosis
por: Sharma, Praveen, et al.
Publicado: (2010)

Efficacy of long-term rifaximin treatment for hepatic encephalopathy in the Japanese
por: Nishida, Shinya, et al.
Publicado: (2019)

Rifaximin ameliorates intestinal inflammation in cirrhotic patients with hepatic encephalopathy
por: Tamai, Yasuyuki, et al.
Publicado: (2021)

Add-on Therapeutic Effects of Rifaximin on Treatment-resistant Hepatic Encephalopathy
por: Hayakawa, Yuka, et al.
Publicado: (2022)

Effect of Rifaximin, Probiotics, and l-Ornithine l-Aspartate on Minimal Hepatic Encephalopathy: A Randomized Controlled Trial
por: Sharma, Kapil, et al.
Publicado: (2014)

Rifaximin as a rare cause of rhabdomyolysis in cirrhosis
por: Rezigh, Alec B., et al.
Publicado: (2018)

Rifaximin has the potential to prevent complications of cirrhosis
por: Flamm, Steven L., et al.
Publicado: (2018)

Detection of Minimal Hepatic Encephalopathy in Iranian Patients with Cirrhosis
por: Khodadoostan, Mahsa, et al.
Publicado: (2018)

A New-Onset Rash in the Setting of Rifaximin Treatment for Hepatic Encephalopathy
por: Fritz, Cassandra D.L., et al.
Publicado: (2014)

Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients
por: Nakai, Masato, et al.
Publicado: (2022)

Efficacy of Switching from Kanamycin Sulfate to Rifaximin in Patients with Hepatic Cirrhosis
por: Tatsumi, Ryoji, et al.
Publicado: (2020)

Small Intestinal Bacterial Overgrowth Diagnosed by a Breath Test and Improved by Rifaximin in a Patient with Hepatic Encephalopathy and Alcoholic Liver Cirrhosis
por: Sakamaki, Akira, et al.
Publicado: (2020)

Neurofilament Light Chain Protein in Plasma and Extracellular Vesicles Is Associated with Minimal Hepatic Encephalopathy and Responses to Rifaximin Treatment in Cirrhotic Patients
por: Fiorillo, Alessandra, et al.
Publicado: (2023)

Comparison of Rifaximin and Lactulose for the Treatment of Hepatic Encephalopathy: A Prospective Randomized Study
por: Paik, Yong-Han, et al.
Publicado: (2005)

Rifaximin versus Nonabsorbable Disaccharides for the Treatment of Hepatic Encephalopathy: A Meta-Analysis
por: Wu, Dong, et al.
Publicado: (2013)

Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin
por: Neff, Guy, et al.
Publicado: (2018)

Rifaximin ameliorates hepatic encephalopathy and endotoxemia without affecting the gut microbiome diversity
por: Kaji, Kosuke, et al.
Publicado: (2017)

Long-term management of hepatic encephalopathy with lactulose and/or rifaximin: a review of the evidence
por: Hudson, Mark, et al.
Publicado: (2019)

Combination of rifaximin and lactulose improves clinical efficacy and mortality in patients with hepatic encephalopathy
por: Wang, Zhida, et al.
Publicado: (2018)

Recurrence of Hepatic Encephalopathy after TIPS: Effective Prophylaxis with Combination of Lactulose and Rifaximin
por: Seifert, Leon Louis, et al.
Publicado: (2021)

Is rifaximin better than nonabsorbable disaccharides in hepatic encephalopathy?: A meta-analysis
por: Cheng, Junxiong, et al.
Publicado: (2021)

Effects of Low-dose and High-dose Rifaximin in the Treatment of Covert Hepatic Encephalopathy
por: Tan, Wei, et al.
Publicado: (2022)

Motor and Cognitive Performance in Patients with Liver Cirrhosis with Minimal Hepatic Encephalopathy
por: San Martín-Valenzuela, Constanza, et al.
Publicado: (2020)

Current approach to treatment of minimal hepatic encephalopathy in patients with liver cirrhosis
por: Moran, Segundo, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_p56m6mcuvldf3jpjdskml2nl2n